The Involvement of Human Gut Microbiota in Chronic Systemic Inflammation | CMAC

The Involvement of Human Gut Microbiota in Chronic Systemic Inflammation

Clinical Microbiology and Antimicrobial Chemotherapy. 2015; 17(4):310-317

​ Kashtanova D.A., Egshatyan L.V., Tkacheva O.N.
chronic inflammation gut microbiota pro-inflammatory mediators lipopolysaccharide lipoteichoic acid peptidoglycan regulatory T-cells
Section
Personal Experience
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2015; 17(4):310-317

Abstract

This article presents current view about the mechanisms of human gut microbiota influence on chronic systemic inflammation. Over the last years, evidence of close relationship between different medical conditions and gut microbiota status has been obtained. Epidemiological and clinical studies confirmed an association between immune system function and gut microbiota composition. Also, it has been found that qualitative and quantitative changes in gut microbiota could induce or inhibit chronic inflammation and, therefore, influence on the development of non-infectious diseases, such as type 2 diabetes, cardiovascular diseases, allergic reactions etc.

Darya A. Kashtanova

National Research Center for Preventive Medicine, Moscow, Russia

Lilit V. Egshatyan

National Research Center for Preventive Medicine, Moscow, Russia

Tkacheva O.N.

National Research Center for Preventive Medicine, Moscow, Russia

  • 1. Булатова ЕМ, Богданова НМ. Кишечная микрофлора - один из факторов формирования здоровья человека. ГОУ ВПО «Санкт-Петербургская государственная педиатрическая медицинская академия Росздрава», «Медицинский совет» № 01 (2013) С. 30-31.
  • 2. Bik E.M., Eckburg P.B., Gill S.R., et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci USA 2006; 103:732-7.
  • 3. Qin J., Li R., Raes J., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464:59-65.
  • 4. Sekelja M., Berget I., Rudi K. Unveiling an abundant core microbiota in the human adult colon by a phylogroupindependent searching approach. ISME J 2011; 5:519-31.
  • 5. Патофизиология под ред. В.В. Новицкого, Е.Д. Гольдберга, О.И. Уразовой. 2012. Том 1, гл. 10, С. 660.
  • 6. Соломатина Л.В. Роль хронического системного воспаления в патогенезе терминальной почечной недостаточности у пациентов, получающих заместительную терапию программным гемодиализом. Автореферат диссертации 2012 г.
  • 7. Вельков В.В. С-реактивный белок в лабораторной диагностике острых воспалений и в оценке рисков сосудистых патологий. Клинико-лабораторный консилиум. 2008; 2(21):37-48
  • 8. Thjodleifsson B., Olafsson I., Gislason D., et al. Infections and obesity: a multinational epidemiological study. Scand J Infect 2008; 40:381-6.
  • 9. Liu A.H., Redmon A.H. Endotoxin: friend or foe? Allergy and Astma Proc 2001; 22:337-40.
  • 10. Schoeffel U., Pelz K., Haring R.U., et al. Inflammatory consequences of the translocation of bacteria and endotoxin to mesenteric lymph nodes. Am J Surg 2000; 180:65-72.
  • 11. Cani P.D., Bibiloni R., Knauf C., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57:1470-81.
  • 12. Ben-Baruch A., Michiel D., Oppenheim J. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem 1995; 270:11703-6.
  • 13. Brightbill H., Modlin R. Toll-like receptors: molecular mechanisms of the mammalian immune response. Immunology 2000; 101:1-10.
  • 14. Rock F.L.; Hardiman G., Timans J.C., Kastelein R., Bazan J.F. A family of human receptors structurally related to Drosophila Toll. Proc. National Academy of Sciences USA 1998; 95:588-93.
  • 15. Fitzgerald K.A., Rowe D.C., Golenbock DT. Endotoxin recognition and signal transduction by the TLR4/ MD2-complex. Microbes Infect 2004; 6:1361-7.
  • 16. Lee J., Hwang D.H. The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors. Molecules and Cells 2006; 21(2):174-85.
  • 17. Tsukamoto H., Fukudome K., Takao S., et al. Lipopolysaccharide-binding protein-mediated Toll-like receptor 4 dimerization enables rapid signal transduction against lipopolysaccharide stimulation on membrane-associated CD14-expressing cells. Int Immunol 2010; 22(4):271-80.
  • 18. Gangloff S., Hijiya N., Haziot A., et al. Lipopolysaccharide structure influences the macrophage response via CD14-independent and CD14-dependent pathways. Clin Inf Dis 1999; 28:491-6.
  • 19. Biagi B., Nylund L., Candela M., et al. Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010; 5:10667.
  • 20. Cani P.D., Amar J., Iglesias M.A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56:1761-72.
  • 21. Хавкин А.И. Микрофлора и развитие иммунной системы. Вопросы современной педиатрии 2012; 11(5):86-9.
  • 22. Ebert O., Ropke G., Marten A., Buttgereit P. TNF-a secretion and apoptosis of lymphocytes mediated by gene transfer. Cytokines and Cell Molecular Therapy 1999; 5(3):165-73.
  • 23. Маянский А.Н., Чеботарь И.В., Фокина Ю.В. Реактивность к пептидогликану стафилококков в системе «нейтрофил-эндотелий». ЖМЭИ 1995; 4:75-8.
  • 24. Archibald A.R., Hancock I.C., Harwood C.R. Cell wall struc ture, synthesis, and turnover. A.L.So nenshein, J.A.Hoch, and R.Lo sick eds., American Society for Microbiology, 1993. 381-410.
  • 25. Fischer W. Lipoteichoic acid and lipids in the membrane of Staphylococcus aureus. Med Microbiol Immunol 1994; 183(2):61-76.
  • 26. Courtney H.S., Hasty D.L., Dale J.B. Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci. Ann. Med 2002; 34(2):77-87.
  • 27. Collins M., Lawson P., Willems A., et al. The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Bacteriol 1994; 44:812-26.
  • 28. Sokol H., Pigneur B., Watterlot L., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. PNAS2008; 105:16731-6.
  • 29. Железникова Г.Ф., Регуляторные Т-лимфоциты в иммунном ответе на инфекцию, Журнал инфектологии 2011; 3(1):6-13.
  • 30. Ma H.L., Napierata L., Stedman N., et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasislike disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum 2010; 62(2):430-40.
  • 31. Fontenot J.D., Rudensky A.Y. A well adapted regulatory contrivance: regulatory T-cell development and the forkhead family transcription factor Foxp3. Nature Immunol 2005; 6(4):331-7.
  • 32. Bettelli E., Dastrange M., Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NFκ to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA 2005; 102:5138-43.
  • 33. Gambineri E., Torgerson T., Ochs H. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance, a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003; 15(4):430-5.
  • 34. Pandolfi F., Cianci R., Pagliari D., et al. Cellular mediators of inflammation: Tregs and TH17 cells in gastrointestinal diseases. Mediators Mediators Inflamm 2009; DOI 10.1155/2009/132028.
  • 35. Tang Q., Bluestone J. The Foxp3+ regulatory T cell: A jack of all trades, master of regulation. Nat Immunol 2008; 9:239-44.
  • 36. Елисеева Д.Д., Завалишин И.А., Караулов А.В. Роль регуляторных Т-клеток в развитии аутоиммунных нарушений при рассеянном склерозе. Вестник РАМН 2012; 3:68-74.
  • 37. Piccirillo C.A., Shevach E.M. Naturally-occurring CD4+CD25+ immunoregulatory T-cells: central players in the arena of peripheral tolerance. Semin Immunol 2004; 16(2):81-8.
  • 38. Pronio A., Montesani C., Butteroni C., et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 2008; 14:662-8.
  • 39. Lorea B.M., Kirjavainen P.V., Hekmat S., et al. Antiinflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 2007; 149:470- 9.
  • 40. Maslowski K.M., Vieira A.T., Aylwin N., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461:1282-6.
  • 41. Kumari R., Ahuja V., Jaishree P. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World J Gastroenterol 2013; 19:3404-14.
  • 42. Fredstrom S.B. Apparent fiber digestibility and fecal short chain fatty acid concentrations with ingestion of two types of dietary fiber. JPEN J Parenter Enteral Nutr 1994; 18:14-9.
  • 43. Meijer K., de Vos P., Priebe M.G. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health. Curr Opin Clin Nutr Metab Care 2010; 13:715-21.
  • 44. Hamer H.M., Jonkers D., Venema K., et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27:104-19.
  • 45. Sokol H., Pigneur B., Watterlot L., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 28:16731-6.
  • 46. Harig J.M., Soergel K.H., Komorowski R.A., Wood C.M. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 1989; 32:23-8.
  • 47. Vernia P., Marcheggiano A., Caprilli R., et al. Aliment Short-chain fatty acid topical treatment in distal ulcerative colitis. Pharmacol Ther 1995; 9:309-13.
  • 48. Brown A.J., Goldsworthy S.M., Barnes A.A., et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003; 278:11312-9.
  • 49. Maslowski K., Vieira A., Aylwin N., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461:1282-6.
  • 50. Tsun J.G., Shiu S.W., Wong Y., et al. Impact of serum amyloid A on cellular cholesterol efflux to serum in type 2 diabetes mellitus. 2013; 231:405-10.
  • 51. Саркисова И.А. Ревматоидный артрит как ведущая причина развития вторичного АА-амилоидоза. Клиническая геронтология 2009; 2:14-20.
  • 52. Kumon Y., Sueehiro Т., Ikeda Y., et al. Influence of serum amyloid A protein on high density lipoprotein in chronic inflammatory disease. Clin Biochem 1993; 26:505-11.
  • 53. Faty А., Ferré Р., Commans S. The acute phase protein serum amyloid A induces lipolysis and inflammation in human adipocytes through distinct pathways. PLoS One 2012; 7:1.
  • 54. Migita K., Eguchi K., Tsukada T., et al. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Laboratory Investigation 1996; 75:371-5.
  • 55. Reigstad C.S., Lundén G.O., Felin J., et al. Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota. PLoS ONE2009; 4(6): DOI: 10.1371/journal.pone.0005842.
  • 56. Poitou C., Coussieu C., Rouault C., et al. Serum amyloid A: a marker of adiposity-induced low-grade inflammation but not of metabolic status obesity. Silver Spring 2006; 14(2):309-18.
  • 57. Мечников И.И. Этюды оптимизма. Наука, 1964. с. 124.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared